Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 131 Gastrointestinal Stromal Tumors 67 Leukemia 66 Leukemia, Myeloid, Chronic-Phase 47 Precursor Cell Lymphoblastic Leukemia-Lymphoma 41 Blast Crisis 22 Brain Neoplasms 15 Philadelphia Chromosome 14 Melanoma 13 Sarcoma 12 Neoplasms 12 Neoplasm Metastasis 12 Leukemia, Myeloid, Acute 12 Leukemia, Myeloid, Accelerated Phase 12 Glioblastoma 12 Lung Neoplasms 11 Prostatic Neoplasms 10 Leukemia, Myeloid 9 Gliosarcoma 9 Glioma 8 Breast Neoplasms 8 Primary Myelofibrosis 7 Leukemia, Myelomonocytic, Chronic 7 Central Nervous System Neoplasms 7 Astrocytoma 7 Recurrence 6 Polycythemia Vera 6 Ovarian Neoplasms 6 Oligodendroglioma 6 Myeloproliferative Disorders 6

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × Imatinib Mesylate × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡